Last reviewed 2026-04-19 · How we verify

FECLOBUZONE

Phase 2 active Small molecule

FECLOBUZONE is a feclobuzone drug. It is currently in Phase 2 development.

FECLOBUZONE is a small molecule that works by interacting with a specific biological target, but its exact mechanism of action is unknown.

FECLOBUZONE is a small molecule drug of the feclobuzone class, but details about its development, approval status, and commercial availability are limited. Its target and mechanism of action are unknown. As a result, there is no information available on its approved indications, half-life, bioavailability, or generic manufacturers. Further research is needed to understand the pharmacological properties and clinical applications of FECLOBUZONE. Its commercial status and safety considerations are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FECLOBUZONE
Drug class	feclobuzone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, there is no clear explanation of how FECLOBUZONE works, as its target and mechanism of action have not been fully elucidated. This lack of information makes it difficult to understand how the drug might interact with the body or produce its effects. More research is needed to shed light on its pharmacological properties.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FECLOBUZONE CI brief — competitive landscape report
FECLOBUZONE updates RSS · CI watch RSS

Frequently asked questions about FECLOBUZONE

What is FECLOBUZONE?

FECLOBUZONE is a feclobuzone drug.

How does FECLOBUZONE work?

FECLOBUZONE is a small molecule that works by interacting with a specific biological target, but its exact mechanism of action is unknown.

What drug class is FECLOBUZONE in?

FECLOBUZONE belongs to the feclobuzone class. See all feclobuzone drugs at /class/feclobuzone.

What development phase is FECLOBUZONE in?

FECLOBUZONE is in Phase 2.

Drug class: All feclobuzone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing